Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FAM-NP41 for Cranial Nerve Visualization in Neurosurgery
NCT05043519Phase 2Unknown
- Sponsor
- Peking University Third Hospital
- Start
- Jan 2022
- Primary completion
- Aug 2023
- Modality
- Small Molecules, Peptide-Drug Conjugates
01
Overview
Phase 2, open-label, single-arm trial of bevonescein in cranial nerve injury, sponsored by Peking University Third Hospital. Primary endpoints: Pharmacokinetic parameters, Hepatorenal functions and 1 more. Status: unknown.
02
Drugs
bevonescein
03
Conditions
cranial nerve injury
Beyond the preview
Go deeper on NCT05043519.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05043519.